Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors
© Sahu and Cloyd; licensee BioMed Central Ltd. 2011
Received: 26 July 2011
Accepted: 12 August 2011
Published: 12 August 2011
Recently, there is considerable interest in the field of anti-HIV therapy to identify and develop chromatin-modifying histone deacetylase (HDAC) inhibitors that can effectively reactivate latent HIV in patients. The hope is that this would help eliminate cells harboring latent HIV and achieve an eventual cure of the virus. However, how effectively these drugs can stimulate latent HIVs in quiescent primary CD4 T cells, despite their relevant potencies demonstrated in cell line models of HIV latency, is not clear. Here, we show that the HDAC inhibitors valproic acid (VPA) and trichostatin A (TSA) are unable to reactivate HIV in latently infected primary CD4 T cells generated in the H80 co-culture system. This raises a concern that the drugs inhibiting HDAC function alone might not be sufficient for stimulating latent HIV in resting CD4 T cells in patients and not achieve any anticipated reduction in the pool of latent reservoirs.
List of abbreviations
Human Immunodeficiency virus-1
Highly active anti-retroviral therapy
- SCID-hu (Thy/Liv):
Severe combined immunodeficiency-human (thymus/liver).
The presence of resting memory CD4 T lymphocytes that harbor chromosomally integrated latent HIVs has been one of the major obstacles in eliminating HIV from patients using HAART [1, 2]. Although the frequencies of these cells in vivo are very low (i.e., ~1-10 latently infected cells per million CD4 T cells), these highly stable cells serve as a life-long reservoir for HIV in infected individuals, despite long-term effective therapy . To attain an eventual cure for HIV, if ever achievable, the elimination of these cells from patients is necessary, which remains extremely challenging and it is not clear how that can be achieved.
The mechanisms involved in HIV latency are multifactorial  and one of the underlying mechanisms found for the maintenance of latent HIV in transformed cell lines is the chromatin-mediated suppression of viral mRNA synthesis from the HIV LTR . The treatment of latently infected cell lines with HDAC inhibitors, such as valproic acid (VPA) or trichostatin A (TSA), can increase the levels of histone acetylation [6, 7], leading to changes in local chromatin organization at the latent HIV LTR [8–10]. This disruption of compact chromatin structure at the LTR causes higher levels of HIV transcription, resulting in the reactivation of latent HIV  and production of viral progeny in cell lines. Therefore, recent thrusts in the field are to identify potent HDAC inhibitors and use them clinically, because the assumption is that once HDAC inhibitors reactivate latent HIVs in resting CD4 T cells in patients, these cells will die because of virus-induced cytopathicity and/or HIV-specific cell-mediated immunity which is present. However, it is not entirely clear if these drugs can stimulate latent HIVs in primary CD4 T cells.
We have previously shown the formation of latent HIV at high-percentages in HIV-infected primary CD4 T cells in vitro using a feeder cell line, H80 , to keep the lymphocytes alive and healthy. Here, we have tested whether valproic acid or trichostatin A (both are HDAC inhibitors) can stimulate HIV in latently infected primary CD4 T cells generated in our H80 co-culture system.
Results and Discussion
We generated latently HIV-infected primary T cells as previously described . Briefly, we started with purified CD4 T cells from normal donors' blood. Cells were stimulated with cross-linked anti-CD3 on plastic dishes for 2 days. Then the cells were scrapped off and cultured in IL-2 media for 5 days, and were infected with a frozen stock of a CXCR4-dependent, low cytopathic HIV strain, MCK, at m.o.i. ~1. The infected cells were cultured for 2-3 weeks and then co-cultured on the H80 feeder cell line for 6 weeks as described previously . Typically, ~5-10% of the CD4 cells present are latently infected by this time point.
Changes in the percentages of p24+ cells in HIV-infected quiescent cultures upon treatment with various chemicals
Chemicals used to stimulate latent HIVs in primary T cells
Average % p24+ cells determined by flow cytometry
in average % p24+ cells in treated vs. untreated groups
18.9 ± 4.3
Prostratin (500 nM)
33.7 ± 4.2
VPA (2 mM)
18.0 ± 6.2
TSA (150 nM)
17.1 ± 3.0
To measure the relative levels of HIV RNA in treated versus untreated HIV-infected primary T cells, we carried out real-time quantitative RT-PCR for HIV-gag sequences as follows: total RNA isolated was quantified using a Nanodrop Spectrophotometer (Nanodrop Technologies) and qualified by analysis on an RNA Nanochip using the Agilent 2100 Bioanalyzer (Agilent Technologies). Synthesis of cDNA was performed with 1 μg of total RNA in a 20 μl reaction volume for 30 min at 48°C using the reagents in the Taqman Reverse Transcription Reagents Kit (Applied Biosystems). Real-time quantitative PCR amplifications were performed in triplicates using 2 μl of cDNA in a total volume of 25 μl using TaqMan MGB probe with the TaqMan Universal PCR Master Mix (Applied Biosystems). The final concentration of the probe was 250 nM and of the primers were 900 nM. Based on the HIV strain (HIV-MCK) used in our experiments, the designed probe sequence was 5'-ACCCCACAAGATTTAAA-3', and the primer sequences were: forward, 5'-AATACCCATGTTTTCAGCATTATCAGA-3' and reverse, 5'-TGATGTCCCCCCACTGT GTT-3'. Relative quantitative RT-PCR assays were performed with 18S RNA as a normalizer. All PCR assays were run in the ABI Prism 7000 Sequence Detection System and the conditions were as follows: initial incubation (50°C for 2 min) and denaturation (95°C for 10 min) steps were followed by 40 cycles of amplification (each cycle: 95°C for 15 sec and 60°C for 1 min). The analysis showed that prostratin-treatment could increase HIV-RNA levels by 1.7-fold (p < 0.01) as shown in Figure 3E, with a concomitant increase in the percentages of HIV-p24+ cells by ~1.8-fold (see Table 1). In contrast, HIV-RNA levels in latently-infected primary T cells remained unchanged after VPA-treatment (Figure 3E) as did the percentages of HIV-p24 positive cells (Table 1). These data presented here demonstrate that latent HIVs in primary quiescent CD4 T-lymphocytes are not responsive to the HDAC-inhibitors VPA or TSA.
One of the recent thrusts in the field of HIV treatment focuses on identifying potent HDAC-inhibitors for use clinically as an adjunct therapy to HAART. This endeavor stems mainly from previous observation by Lehrman et. al.  who showed the reduction in the pool of latently infected resting CD4 T cells by ~75% in 3 of 4 patients when treated with VPA in combination with suppressive HAART. This study, although not definitive, suggested the possibility that the current antiviral regimens plus additional drugs targeting latent reservoirs may attain cures of HIV in chronically infected patients. Although subsequent studies by others did not find similar effects of VPA on latent reservoir in patients [13, 14], these studies opened up new avenues for antiviral research aiming to break HIV latency in resting CD4 T cells in order to achieve depletion of latently infected cells in patients on HAART. However, our data demonstrate that VPA or TSA are unable to drive the expression of virus from its latent state in primary resting CD4 T cells, in contrast to their well-documented effectiveness in transformed, actively dividing cell line models of HIV latency. Our data are also in agreement with the previous observation by Brooks et. al.  who did not observe reactivation of latent HIV in primary T cells obtained from the SCID-hu (Thy/Liv) mouse model of HIV-latency.
Although we do not know whether VPA or TSA can remodel chromatin organization at HIV LTRs in latently infected primary T lymphocytes generated in our culture system, the requirements for reactivating latent HIVs appear multifactorial . For example, resting T cells possess limiting amounts of various transcription factors, such as activated nuclear NF-kB, Cyclin T1 and Cdk9 required for productive transcription to occur from the HIV LTR [16, 17]. There is no evidence indicating that VPA or TSA-treatment can induce the expression of these factors in resting primary CD4 T cells or activate these cells. As a cautionary note, our data predict that the use of HDAC-inhibitors as adjunct therapy in the "shock and kill" approach for depleting latent reservoirs in patients would not be fruitful, unless simultaneous activation or induction of expression of cellular factors (such as NF-kB, CycT1, Cdk9 etc.) essential for high-level HIV gene expression is achieved in resting CD4 T cells.
It is worthwhile to mention that during the last decade, latently infected transformed T cell clones have been extensively used in the context of mechanistic studies of the establishment and the maintenance of HIV latency and its reactivation from the latent state. However, many of these clones were isolated by screening and selecting the clones that were responsive to TNF-α-mediated stimulation of latent HIV constructs . Recently Tyagi et. al.  have used the H80 system to generate latently infected primary T cells at high-percentages in vitro using pseudotyped HIV (negative for its own envelope), and found TNF-α could not reactivate latent HIVs in these cells. This is because of restricted cellular levels of P-TEFb (CDK-9, CycT1) in spite of nuclear NF-kB activation by TNF-α signaling in these cells . Although we generated latently infected primary T-cells in the H80 system using infectious Env+ HIV at lower percentages than what Tyagi et. al.  did; we, likewise, did not observe activation of latent HIV in these cells upon TNF-α treatment (data not shown). Altogether, our and others data obtained from HIV-infected primary T cells cultured on H80 strongly advocate for studying HIV latency in non-dividing quiescent normal CD4 T cells, rather than in transformed, actively dividing cell lines.
This work was supported by grants from NIH (R01AI062453) and the Clayton Foundation for Research to MWC.
- Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.[see comment]. Science 1997, 278:1295–1300.PubMedView Article
- Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.[see comment]. Science 1997, 278:1291–1295.PubMedView Article
- Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine 2003, 9:727–728.PubMedView Article
- Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF: The multifactorial nature of HIV-1 latency. Trends Mol Med 2004, 10:525–531.PubMedView Article
- Choudhary SK, Margolis DM: Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol 2011, 51:397–418.PubMedView Article
- Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN: Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005, 65:3815–3822.PubMedView Article
- Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734–36741.PubMedView Article
- Jordan A, Defechereux P, Verdin E: The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. Embo J 2001, 20:1726–1738.PubMedView Article
- He G, Margolis DM: Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 2002, 22:2965–2973.PubMedView Article
- Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC: NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Embo J 2006, 25:139–149.PubMedView Article
- Sahu GK, Lee K, Ji J, Braciale V, Baron S, Cloyd MW: A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 2006, 355:127–137.PubMedView Article
- Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549–555.PubMedView Article
- Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Paller C, Delfraissy JF, Lambotte O: Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. Aids 2008, 22:1125–1129.PubMedView Article
- Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J Jr, Moore RD, Gange SJ, Siliciano RF: Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007, 195:833–836.PubMedView Article
- Brooks DG, Arlen PA, Gao L, Kitchen CM, Zack JA: Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci USA 2003, 100:12955–12960.PubMedView Article
- Price DH: P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000, 20:2629–2634.PubMedView Article
- Ghose R, Liou LY, Herrmann CH, Rice AP: Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J Virol 2001, 75:11336–11343.PubMedView Article
- Jordan A, Bisgrove D, Verdin E: HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J 2003, 22:1868–1877.PubMedView Article
- Tyagi M, Pearson RJ, Karn J: Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010, 84:6425–6437.PubMedView Article
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.